Mytos has entered into a manufacturing collaboration with Aspen Neuroscience to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease.
Cartherics Pty has announced that it has been awarded a $300K G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
SpliceBio has announced that the U.S. Food & Drug Administration (FDA) has cleared its investigational new drug (IND) application for lead program SB-007.
iotaSciences announced the upcoming launch of its newly developed Single-Cell Cloning Platform XT at the Cell 2024 event in London (UK) from November 6-8, 2024.
Ahead of CPHI Milan, EPM spoke to Hayley Crowe, executive vice president and general manager of Ecolab's Global Life Sciences sector, to discuss the company's approach to addressing the growing demand of cell and gene therapies (C>s).
Alcura, a provider of specialised clinical trial services and a part of Cencora, has been granted a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) by the Spanish Agency of Medicines and Medical Devices.
Justin Wilson, partner and pharmaceuticals & gene therapy sector specialist at European intellectual property law firm Withers & Rogers explores how patent lifecycle management is key for cell and gene therapy innovators.
Adriano Leuzzi, Head of Process Development and Angelo Raggioli, Head of Technology Development at ReiThera explore the advancements and challenges in bioprocessing for viral-vector gene therapy manufacturing in our latest EPM Online insight.
